Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Income from Continuing Operations (2019 - 2026)

Pliant Therapeutics has reported Income from Continuing Operations over the past 8 years, most recently at 20040000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations rose 64.32% to 20040000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 111390000.0 through Mar 2026, up 49.26% year-over-year, with the annual reading at 147516000.0 for FY2025, 29.86% up from the prior year.
  • Income from Continuing Operations was 20040000.0 for Q1 2026 at Pliant Therapeutics, up from 21749000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 20040000.0 in Q1 2026 and troughed at 57763000.0 in Q3 2024.
  • The 5-year median for Income from Continuing Operations is 41109000.0 (2023), against an average of 38971588.24.
  • Year-over-year, Income from Continuing Operations crashed 42.92% in 2022 and then surged 64.32% in 2026.
  • A 5-year view of Income from Continuing Operations shows it stood at 35060000.0 in 2022, then fell by 17.25% to 41109000.0 in 2023, then decreased by 20.98% to 49732000.0 in 2024, then skyrocketed by 56.27% to 21749000.0 in 2025, then grew by 7.86% to 20040000.0 in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Income from Continuing Operations are 20040000.0 (Q1 2026), 21749000.0 (Q4 2025), and 26301000.0 (Q3 2025).